Back to All

The critical role of lab data in commercial and clinical development tactics

28 April, 2022

Featured

Over the past two years, COVID-19 has affected almost every area of healthcare, with a major impact in oncology.  

During the pandemic, healthcare resources were redistributed in response to COVID-19, resulting in the process of testing, diagnosis and treatment of patients significantly delayed, particularly in oncology and rare diseases. A survey conducted by Breastcancer.org in April 2020 found that in 534 patients, 22% reported that they had a delay in screening, 31.7% reported a delay in care and 9.3% reported a delay in treatment as a result of COVID-19 in the United States. As a result of delayed screening, postponed surgeries and treatment, cases of advanced cancers are predicted to increase over the coming years.  

Effectively diagnosing and treating patients is a key priority as the healthcare industry seeks to ensure patients receive the most effective treatment possible. 

Lab testing 

Diagnostic laboratories are an essential part of any healthcare system and are one of the early and critical points in a patient's journey to diagnosis and ultimately treatment.  

Lab testing enables Healthcare Professionals (HCPs) to correctly diagnose patients and ensure they receive the treatment they need to have the best possible outcomes. For pharma, this is the earliest possible point in which potentially eligible patients can be identified for a new treatment or enrollment in a clinical trial.  

Lab data has become a critical component of life sciences commercial and clinical development tactics, by providing actionable alerts to support sales force effectiveness and clinical trial recruitment.  

Due to its critical nature, data supply chain management is important. Data providers have fallen into two categories: single labs, and aggregators. Single labs do not provide a broad representation across the whole of the US, whilst aggregators have been prone to insecurity in the labs providing them data. In both situations, trigger programs may be sub-optimal and in response to this, Diaceutics has developed DXRX Signal to overcome these limitations. 

DXRX Signal is powered by real-world data from 493 labs in the US, these labs provide broad representation from academic, community and commercial labs. This diverse dataset ensures reliability through dedicated supply chain management and multi-year contracting. DXRX Signal benefits clients by finding patients across a wide range of conditions including oncology, rare diseases, auto-immune, cardiovascular, and infectious diseases. 

Delivering results  

DXRX Signal helps the pharma industry to build robust precision data operations by identifying patients at the earliest possible stage of diagnosis and matching those eligible patients to targeted therapies. The ability to follow the patient's journey from initial testing to diagnosis and any changes to the patient response enables the specificity and focus for sales and marketing targeting, resulting in increased sales and market penetration.  

Want to learn more about DXRX Signal? Get in touch to request a demo today 

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane
London
EC4V 5EQ.

Tel: +44 (0)20 3405 0205 or [email protected]


 
Caroline Forde
Robyn Fisher
 
Kieran Breheny